Progenics Inked a Merger to Avoid Negotiating a Proxy War. One Activist Still Wants to Fight
Locked in a proxy tussle with activist investor Velan Capital, Progenics Pharmaceuticals danced a sidestep, inking a merger deal with another company rather than negotiate with its board challengers. But now, Velan says it's not giving up the fight—and the proposed merger has joined its list of grievances...
Login to comment.